BIOMAT Database Logo BIOMAT Database Logo

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. 2000

P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63108, USA. tebas@im.wustl.edu

BACKGROUND The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time. METHODS We performed a cross-sectional analysis of whole-body, lumbar spine (L1-L4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry. RESULTS Men receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk = 2.19 (95% confidence interval 1.13-4.23) (P = 0.02). Subjects receiving protease inhibitors had greater central: appendicular adipose tissue ratios than the other two groups (P < 0.0001). There was no relationship between the central: appendicular fat ratio and the lumbar spine or proximal femur bone mineral density t- or z- scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART. CONCLUSIONS Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015502 Absorptiometry, Photon A noninvasive method for assessing BODY COMPOSITION. It is based on the differential absorption of X-RAYS (or GAMMA RAYS) by different tissues such as bone, fat and other soft tissues. The source of (X-ray or gamma-ray) photon beam is generated either from radioisotopes such as GADOLINIUM 153, IODINE 125, or Americanium 241 which emit GAMMA RAYS in the appropriate range; or from an X-ray tube which produces X-RAYS in the desired range. It is primarily used for quantitating BONE MINERAL CONTENT, especially for the diagnosis of OSTEOPOROSIS, and also in measuring BONE MINERALIZATION. Absorptiometry, X-Ray,Dual-Photon Absorptiometry,Photodensitometry, X-Ray,Photon Absorptiometry,Single-Photon Absorptiometry,X-Ray Absorptiometry,Absorptiometry, Dual X-Ray,Absorptiometry, Dual-Energy Radiographic,Absorptiometry, Dual-Energy X-Ray,DEXA Scan,DPX Absorptiometry,DXA Scan,Densitometry, X-Ray,Densitometry, Xray,Dual X-Ray Absorptiometry,Dual-Energy Radiographic Absorptiometry,Dual-Energy X-Ray Absorptiometry,Dual-Energy X-Ray Absorptiometry Scan,Radiographic Absorptiometry, Dual-Energy,X-Ray Absorptiometry, Dual-Energy,X-Ray Photodensitometry,Absorptiometries, DPX,Absorptiometry, DPX,Absorptiometry, Dual Energy Radiographic,Absorptiometry, Dual Energy X Ray,Absorptiometry, Dual X Ray,Absorptiometry, Dual-Photon,Absorptiometry, Single-Photon,Absorptiometry, X Ray,DEXA Scans,DXA Scans,Densitometry, X Ray,Dual Energy Radiographic Absorptiometry,Dual Energy X Ray Absorptiometry,Dual Energy X Ray Absorptiometry Scan,Dual Photon Absorptiometry,Dual X Ray Absorptiometry,Photodensitometry, X Ray,Radiographic Absorptiometry, Dual Energy,Scan, DEXA,Scan, DXA,Scans, DEXA,Scans, DXA,Single Photon Absorptiometry,X Ray Absorptiometry,X Ray Absorptiometry, Dual Energy,X Ray Photodensitometry,X-Ray Absorptiometry, Dual,X-Ray Densitometry,Xray Densitometry
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV

Related Publications

P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Bone mineral loss in HIV-positive patients receiving antiretroviral therapy.
September 2000, AIDS (London, England),
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
[Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].
March 2004, Anales de pediatria (Barcelona, Spain : 2003),
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Accelerated bone mineral loss in HIV-positive patients.
April 2000, The AIDS reader,
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Gynecomastia in HIV-infected patients receiving antiretroviral therapy.
September 2003, AIDS research and human retroviruses,
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
June 2010, Bone,
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
September 2003, AIDS (London, England),
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy.
September 2001, AIDS (London, England),
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Diabetes mellitus in HIV-infected patients receiving antiretroviral therapy.
October 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
May 2000, AIDS (London, England),
P Tebas, and W G Powderly, and S Claxton, and D Marin, and W Tantisiriwat, and S L Teitelbaum, and K E Yarasheski
Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.
October 2004, Antiviral therapy,
Copied contents to your clipboard!